Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genomic Health

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

- PMLiVE

UK approval for Seagen’s oral HER2 inhibitor Tukysa

MHRA has authorised drug for HER2-positive advanced breast cancer

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

NICE turns down bluebird bio’s gene therapy Zynteglo

Draft guidance does not recommend routine NHS funding for beta thalassaemia treatment

- PMLiVE

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

JAK inhibitor approved for use in moderate-to-severe RA

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Drug approved in combination with Merck's KGaA's Erbitux

- PMLiVE

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November

- PMLiVE

NICE – but not enough

Why evidence is better than assumption when executing commercial strategy

- PMLiVE

Lilly’s Verzenio scores a win in early-stage breast cancer

Positive data was presented at 2020 ESMO virtual congress

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links